News | April 28, 2023
Laurus Labs Q4 FY23 consolidated PAT drops to to Rs. 102.98 Cr
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
Enabling clinical effectiveness via a fully interoperable and integrated digital pathology solution
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
Bridging the gap between histopathology and molecular pathology
Apollo continues to invest in genomics technology and research for better patient care
The acquisition is a crucial step in LTS' strategy to broaden its portfolio of drug delivery platforms.
SÜDPACK is setting standards in terms of both performance and sustainability
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
Subscribe To Our Newsletter & Stay Updated
